Literature DB >> 28090531

At the crossroads from bench to bedside: luteolin is a promising pharmacological agent against myocardial ischemia reperfusion injury.

Defeng Pan1, Dongye Li2.   

Abstract

Entities:  

Year:  2016        PMID： 28090531      PMCID： PMC5220033          DOI： 10.21037/atm.2016.11.56

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  47 in total

Review 1.  Treatment of Myocardial Ischemia/Reperfusion Injury by Ischemic and Pharmacological Postconditioning.

Authors:  Gerd Heusch
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

Review 2.  Cardioprotection techniques: preconditioning, postconditioning and remote conditioning (basic science).

Authors:  Derek J Hausenloy
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

3.  Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial.

Authors:  Hans Erik Bøtker; Rajesh Kharbanda; Michael R Schmidt; Morten Bøttcher; Anne K Kaltoft; Christian J Terkelsen; Kim Munk; Niels H Andersen; Troels M Hansen; Sven Trautner; Jens Flensted Lassen; Evald Høj Christiansen; Lars R Krusell; Steen D Kristensen; Leif Thuesen; Søren S Nielsen; Michael Rehling; Henrik Toft Sørensen; Andrew N Redington; Torsten T Nielsen
Journal:  Lancet       Date:  2010-02-27       Impact factor: 79.321

4.  Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women.

Authors:  L Yochum; L H Kushi; K Meyer; A R Folsom
Journal:  Am J Epidemiol       Date:  1999-05-15       Impact factor: 4.897

5.  Relation between intake of flavonoids and risk for coronary heart disease in male health professionals.

Authors:  E B Rimm; M B Katan; A Ascherio; M J Stampfer; W C Willett
Journal:  Ann Intern Med       Date:  1996-09-01       Impact factor: 25.391

6.  Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials.

Authors:  Masafumi Kitakaze; Masanori Asakura; Jiyoong Kim; Yasunori Shintani; Hiroshi Asanuma; Toshimitsu Hamasaki; Osamu Seguchi; Masafumi Myoishi; Tetsuo Minamino; Takahiro Ohara; Yoshiyuki Nagai; Shinsuke Nanto; Kouki Watanabe; Shigeru Fukuzawa; Atsushi Hirayama; Natsuki Nakamura; Kazuo Kimura; Kenshi Fujii; Masaharu Ishihara; Yoshihiko Saito; Hitonobu Tomoike; Soichiro Kitamura
Journal:  Lancet       Date:  2007-10-27       Impact factor: 79.321

7.  Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial.

Authors:  Derek J Hausenloy; Peter K Mwamure; Vinod Venugopal; Joanne Harris; Matthew Barnard; Ernie Grundy; Elizabeth Ashley; Sanjeev Vichare; Carmelo Di Salvo; Shyam Kolvekar; Martin Hayward; Bruce Keogh; Raymond J MacAllister; Derek M Yellon
Journal:  Lancet       Date:  2007-08-18       Impact factor: 79.321

8.  Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial.

Authors:  Ziad A Ali; Chris J Callaghan; Eric Lim; Ayyaz A Ali; S A Reza Nouraei; Asim M Akthar; Jonathan R Boyle; Kevin Varty; Rajesh K Kharbanda; David P Dutka; Michael E Gaunt
Journal:  Circulation       Date:  2007-09-11       Impact factor: 29.690

Review 9.  Targeting cell signaling and apoptotic pathways by luteolin: cardioprotective role in rat cardiomyocytes following ischemia/reperfusion.

Authors:  Tongda Xu; Dongye Li; Dehua Jiang
Journal:  Nutrients       Date:  2012-12-12       Impact factor: 5.717

Review 10.  Ischaemic conditioning and reperfusion injury.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  Nat Rev Cardiol       Date:  2016-02-04       Impact factor: 32.419
View more
  1 in total

1.  Network Pharmacology Analysis and Experimental Verification Strategies Reveal the Action Mechanism of Danshen Decoction in Treating Ischemic Cardiomyopathy.

Authors:  Mengnan Liu; Gang Yuan; Gang Luo; Xin Guo; Mingtai Chen; Huayi Yang; Fan He; Tingfu Yang; Xinyue Zhang; Qibiao Wu; Hua Zhou; Sijin Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-02       Impact factor: 2.650
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.